High doses of hydroxychloroquine do not affect viral clearance in patients with SARS‐CoV‐2 infection

Abstract

The use of hydroxychloroquine (HCQ) has been considered a therapeutic option by international guidelines and expert opinions during the first phase of COVID‐19 pandemics, ^1‐10 although scientific evidence remained too scarce to make a definitive recommendation ¹¹. While HCQ use has now been questioned by recent data ⁷, some previous works draw attention to contrasting results on enhanced viral clearance after HCQ treatment ^1‐6,10.